ABCB1 GENE POLYMORPHISMS ARE ASSOCIATED WITH CLINICAL RESPONSE TO NABIXIMOLS IN PATIENTS WITH MULTIPLE SCLEROSIS-RELATED SPASTICITY

BackgroundMultiple Sclerosis (MS) is an autoimmune disease of the central nervous system causing severe symptoms, including spasticity-related pain. Nabiximols (NBX), a drug combining Tetrahydrocannabinol and Cannabidiol, is approved for MS-associated spasticity. Despite NBX efficacy, only 60-70% of patients respond to treatment. This study explores whether genetic polymorphisms in key genes involved in NBX pharmacology influence response to drug. Materials & MethodsThis is a genetic, exploratory study in which MS patients, treated with NBX, were retrospectively enrolled. Polymorphisms in genes related to NBX metabolism (CYP2C9, CYP2C19), efflux (ATP Binding Cassette subfamily B member 1 - ABCB1), and cannabinoid receptors (CNR1, CNR2) were analyzed using Real-Time PCR. ResultsAmong 45 enrolled patients, 29 responded to NBX and 16 did not. Of responders, 38% were homozygous for the T allele in ABCB1 1236C>T (rs1128503), and 48% for the T allele in ABCB1 3435A>T (rs1045642). None of the non-responders carried T allele. The odds ratios for response to NBX of TT homozygotes was 20.5 (95% CI:1.1-376.1, P=0.0039) for rs1128503 and 30.9 (95% CI:1.7-563.2, P=0.0006) for rs1045642. DiscussionThis study suggests a link between genetic profiles and NBX response. If validated in larger studies, these findings could pave the way for personalized therapy for MS-related spasticity.